A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.

Smit, AK; Espinoza, D; Newson, AJ; Morton, RL; Fenton, G; Freeman, L; Dunlop, K; Butow, PN; Law, MH; Kimlin, MG; Keogh, LA; Dobbinson, SJ; Kirk, J; Kanetsky, PA; Mann, GJ; Cust, AE

A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.

Smit, AK Espinoza, D Newson, AJ Morton, RL Fenton, G Freeman, L

Dunlop, K Butow, PN Law, MH Kimlin, MG Keogh, LA Dobbinson, SJ Kirk, J Kanetsky, PA Mann, GJ Cust, AE

Permalink

Publisher:: American Association for Cancer Research
Publication Type:: Journal Article
Citation:: Cancer Epidemiology, Biomarkers and Prevention, 2017, 26, (2), pp. 212-221
Issue Date:: 2017-02

Closed Access

	Filename	Description	Size
	212.pdf		473.72 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Smit, AK
dc.contributor.author	Espinoza, D
dc.contributor.author	Newson, AJ
dc.contributor.author	Morton, RL
dc.contributor.author	Fenton, G
dc.contributor.author	Freeman, L https://orcid.org/0000-0002-5814-3894
dc.contributor.author	Dunlop, K
dc.contributor.author	Butow, PN
dc.contributor.author	Law, MH
dc.contributor.author	Kimlin, MG
dc.contributor.author	Keogh, LA
dc.contributor.author	Dobbinson, SJ
dc.contributor.author	Kirk, J
dc.contributor.author	Kanetsky, PA
dc.contributor.author	Mann, GJ
dc.contributor.author	Cust, AE
dc.date.accessioned	2022-08-26T01:45:01Z
dc.date.available	2016-09-24
dc.date.available	2022-08-26T01:45:01Z
dc.date.issued	2017-02
dc.identifier.citation	Cancer Epidemiology, Biomarkers and Prevention, 2017, 26, (2), pp. 212-221
dc.identifier.issn	1055-9965
dc.identifier.issn	1538-7755
dc.identifier.uri	http://hdl.handle.net/10453/160889
dc.description.abstract	BACKGROUND: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors. METHODS: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (nonpersonalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone-based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values. RESULTS: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3 months (0.40; 95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress. CONCLUSIONS: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. IMPACT: Genomic risk information has potential as a melanoma prevention strategy. Cancer Epidemiol Biomarkers Prev; 26(2); 212-21. ©2016 AACR.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	American Association for Cancer Research
dc.relation.ispartof	Cancer Epidemiology, Biomarkers and Prevention
dc.relation.isbasedon	10.1158/1055-9965.EPI-16-0395
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences
dc.subject.classification	Epidemiology
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Female
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Genetic Counseling
dc.subject.mesh	Genetic Predisposition to Disease
dc.subject.mesh	Genetic Testing
dc.subject.mesh	Humans
dc.subject.mesh	Informed Consent
dc.subject.mesh	Male
dc.subject.mesh	Melanoma
dc.subject.mesh	Middle Aged
dc.subject.mesh	New South Wales
dc.subject.mesh	Patient Education as Topic
dc.subject.mesh	Pilot Projects
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Risk Factors
dc.subject.mesh	Skin Neoplasms
dc.subject.mesh	Young Adult
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Female
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Genetic Counseling
dc.subject.mesh	Genetic Predisposition to Disease
dc.subject.mesh	Genetic Testing
dc.subject.mesh	Humans
dc.subject.mesh	Informed Consent
dc.subject.mesh	Male
dc.subject.mesh	Melanoma
dc.subject.mesh	Middle Aged
dc.subject.mesh	New South Wales
dc.subject.mesh	Patient Education as Topic
dc.subject.mesh	Pilot Projects
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Risk Factors
dc.subject.mesh	Skin Neoplasms
dc.subject.mesh	Young Adult
dc.subject.mesh	Humans
dc.subject.mesh	Melanoma
dc.subject.mesh	Skin Neoplasms
dc.subject.mesh	Genetic Predisposition to Disease
dc.subject.mesh	Risk Factors
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Feasibility Studies
dc.subject.mesh	Pilot Projects
dc.subject.mesh	Genetic Counseling
dc.subject.mesh	Informed Consent
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	New South Wales
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Patient Education as Topic
dc.subject.mesh	Young Adult
dc.subject.mesh	Genetic Testing
dc.title	A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.
dc.type	Journal Article
utslib.citation.volume	26
utslib.location.activity	United States
utslib.for	11 Medical and Health Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Genetic Counselling
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-08-26T01:45:00Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	26
utslib.citation.issue	2

Abstract:

BACKGROUND: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors. METHODS: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (nonpersonalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone-based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values. RESULTS: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3 months (0.40; 95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress. CONCLUSIONS: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. IMPACT: Genomic risk information has potential as a melanoma prevention strategy. Cancer Epidemiol Biomarkers Prev; 26(2); 212-21. ©2016 AACR.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160889